ReviewCurrent treatment options in oncology2017
Novel Agents in the Treatment of Thymic Malignancies.
Review in Current treatment options in oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- Case Report: Robust and durable response to the combination of tislelizumab and chemotherapy in advanced thymic epithelial tumors: a case series.Frontiers in immunology · 2025Article
- Current immunotherapy for thymic epithelial tumors: a narrative review.Mediastinum (Hong Kong, China) · 2024Review
- Poor efficacy of immune checkpoint inhibitor treatment in advanced thymic carcinoma patients with liver metastases.Therapeutic advances in medical oncology · 2024Article
- Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives.Molecular cancer · 2023Review
- Genomic alterations in thymoma-molecular pathogenesis?Journal of thoracic disease · 2020Review
- Multimodality approach in treatment of thymic tumors.Journal of thoracic disease · 2020Review
- PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Thymic Epithelial Neoplasms.Journal of clinical medicine · 2019Article
- Optimal management of thymic malignancies: current perspectives.Cancer management and research · 2019Article
- Expression of PD-L1/PD-1 in lymphoepithelioma-like carcinoma of the thymus.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018Article
- Uncommon efforts for an uncommon tumor: the case for development of newer systemic therapies for advanced thymic epithelial tumors.Mediastinum (Hong Kong, China) · 2018Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementThe management of thymic tumours is a paradigm of multidisciplinary collaboration. Chemotherapy may be administered part of curative-intent sequential strategy integrating subsequent surgery or radiotherapy, or as an exclusive treatment if local treatment is not achievable. Recurrences of thymic epithelial tumors should be managed according to the same strategy as newly diagnosed tumors. Given the limited activity of cytotoxic agents in the advanced, refractory setting, novel and innovative agents are needed. The better understanding of thymic carcinogenesis may provide a rationale in this setting.Targeted agents approved for other solid tumors that have shown activity in thymic tumors include mTOR, KIT inhibitors, as well as somatostatin analogues. Anti-angiogenic agent sunitinib may be considered a standard in advanced lines of treatment. Ongoing studies are assessing the opportunity of targeting emerging targets, including PI3K, CDK, and immune checkpoint PD-1/PD-L1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.